Skip to content

Topical Analgesia Post-Haemorrhoidectomy

A Prospective, Multicentre, Double-Blinded Randomised Controlled Trial Comparing Topical Metronidazole, Diltiazem and Lidocaine on Post-Operative Pain Following Excisional Haemorrhoidectomy

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04276298
Enrollment
192
Registered
2020-02-19
Start date
2020-09-01
Completion date
2022-02-01
Last updated
2022-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoid Pain, Hemorrhoids

Brief summary

Symptomatic haemorrhoids, or piles, have significant effects on quality of life. The treatment for advanced disease is surgical excision (haemorrhoidectomy) which is extremely effective. However, pain following haemorrhoidectomy is known by all to be a miserable experience and current treatment is not very effective. We have formulated a new cream treatment which targets three theorised mechanisms of pain after haemorrhoidectomy. We will test the effectiveness of the treatments with a multi-centred randomised controlled factorial trial with four parallel double-blinded arms containing different combinations of the active agents. The outcomes include pain scores, amount of analgesia required and time to return to work. The results of our study could provide evidence of an effective treatment for post haemorrhoidectomy pain. The treatment may provide considerable benefit to patients undergoing this surgical procedure.

Detailed description

Study Design: This will be a patient-and-investigator blinded factorial randomised trial with four parallel groups. Participants in all four groups will be instructed to apply cream 3 times a day for 7 days after surgery. A standard analgesia prescription will be provided with laxatives as per routine care. Patients will be provided a questionnaire to complete and return on day 14. Random Sequence Generation: Computer generated sequence allocating patients to a 1:1:1:1 ratio using permuted block randomisation in blocks of 12. Allocation Concealment: This randomisation code will be seeded to the pharmacist to who will package and label the cream according to a code. The creams will be indistinguishable to which active ingredient they contain. Assignment of intervention: Patients will be assigned in order according to the numbering of the cream tubes by the blinded investigator. Data recording: Data will be recorded on Redcap database.

Interventions

10% metronidazole applied rectally

DRUGMetronidazole and Diltiazem cream

Combination Metronidazole and Diltiazem applied rectally

DRUGMetronidazole and Lidocaine cream

Combination metronidazole and lignocaine applied rectally

DRUGMetronidazole, Diltiazem and Lidocaine cream

Combination of all active agents tested applied rectally

Sponsors

University of Auckland, New Zealand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

Double blinded trial, both participant and investigator are blinded.

Intervention model description

Parallel with 1:1:1:1 Allocation.

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥16 * All patients undergoing excisional haemorrhoidectomy

Exclusion criteria

* Age \<16, * history of chronic pain, * drug allergy or idiosyncracies to any actives or excipients in * cream, * breastfeeding, * any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including: * sick sinus syndrome, * atrioventricular block, * hypotension, * heart failure and bradycardia. * concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem. * patients already taking diltiazem.

Design outcomes

Primary

MeasureTime frameDescription
Pain scores7 daysMeasured by visual analog scale, 1-10cm, continuous, the higher the score, the worse the pain
Amount of analgesic use7 daysMorphine equivalent amount

Secondary

MeasureTime frameDescription
Repeat Prescription30 daysRates of Repeat Prescription Requirement
Complications30 daysRates of Bleeding
Pain on bowel motion: Visual Analog Scale7 daysMeasured by Visual Analog Scale, continuous 1-10cm, the higher the score, the worse the pain.
Return to work14 daysDay post-operation when the patient returns to work
Re-admission30 daysRates of Re-admission to hospital,

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026